Kairos Pharma, LTD. SEC filings KAPA
Kairos Pharma, LTD. has 125 filings in SEC EDGAR's recent list, going back to Mar 29, 2023. Its latest annual report, Form ARS, was filed on May 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Nov 3, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 21, 2026 | Aug 21, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 22, 2026 | Jul 16, 2026 |
| 8-K |
Current report
Other events
|
Jul 15, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 30, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Other events
|
Jun 4, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Other events
|
May 18, 2026 | May 18, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Mar 2, 2026 | Mar 2, 2026 |
| 8-K |
Current report
Other events
|
Feb 26, 2026 | Feb 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 15, 2025 | Oct 8, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 7, 2025 | Oct 1, 2025 |
| 8-K |
Current report
Other events
|
Sep 18, 2025 | Sep 18, 2025 |
| 8-K |
Current report
Other events
|
Sep 11, 2025 | Sep 11, 2025 |
| 8-K |
Current report
Other events
|
Sep 3, 2025 | Sep 3, 2025 |
| 8-K |
Current report
Other events
|
Jul 15, 2025 | Jul 15, 2025 |
| 8-K |
Current report
Material agreement, Shareholder vote results
|
Jun 12, 2025 | Jun 10, 2025 |
| 8-K |
Current report
Other events
|
Jun 3, 2025 | Jun 3, 2025 |
| 8-K |
Current report
Auditor change
|
Apr 28, 2025 | Apr 23, 2025 |
| 8-K |
Current report
Other events
|
Apr 24, 2025 | Apr 24, 2025 |
| 8-K |
Current report
Other events
|
Mar 20, 2025 | Mar 20, 2025 |
| 8-K |
Current report
Other events
|
Feb 26, 2025 | Feb 26, 2025 |
| 8-K |
Current report
Other events
|
Feb 6, 2025 | Feb 6, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jan 17, 2025 | Jan 16, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jan 14, 2025 | Jan 14, 2025 |
| 8-K |
Current report
Officer or director change
|
Dec 13, 2024 | Dec 10, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 19, 2024 | Nov 19, 2024 |
| 8-K |
Current report
Other events
|
Oct 10, 2024 | Oct 9, 2024 |
| 8-K |
Current report
Material agreement
|
Oct 4, 2024 | Oct 1, 2024 |
| 8-K |
Current report
Material agreement
|
Sep 27, 2024 | Sep 23, 2024 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 24, 2024 | Sep 20, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 17, 2024 | Sep 16, 2024 |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KAPA (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1962011
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.